Skip to main content
Fig. 1 | Diagnostic Pathology

Fig. 1

From: Erythroid variant evolving from chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitors: a rare case report

Fig. 1

International scale (IS) values (BCR::ABL1/ABL1%) are shown over the course of the disease in relation to TKI treatments, including nilotinib, dasatinib, imatinib, and bosutinib, administered from March 2015 to April 2022. The duration of each TKI treatment is indicated in white boxes, while the reasons for discontinuation, such as drug toxicities, intolerance, and non-adherence, are specified in the black boxes. 2w = 2 weeks

Back to article page

Diagnostic Pathology

ISSN: 1746-1596

Contact us